The novel MAO-B inhibitor PF9601N, its cytochrome P450-dependent metabolite FA72 and l-deprenyl were studied as potential peroxynitrite (ONOO-) scavengers and nitric oxide synthase (NOS) inhibitors. The scavenging activity of these compounds was evaluated by measuring the oxygen consumption through peroxynitrite-mediated oxidation of both linoleic acid and brain homogenate. FA72, PF9601N and l-deprenyl caused a concentration-dependent inhibition of ONOO--induced linoleic acid oxidation with an IC50 value of 60.2 µM, 82.8 µM and 235.8 µM, respectively. FA72 was the most potent also in inhibiting ONOO--induced brain homogenate oxidation with an IC50 value of 99.4 µM, while PF9601N and l-deprenyl resulted weaker inhibitors in the same experimental model, showing an IC50 value of 164.8 and 112.0 µM, respectively. Furthermore, both the novel MAO-B inhibitor as well as its metabolite were able to strongly inhibit rat brain neuronal NOS (IC50 of 183 µM and 192 µM, respectively), while l-deprenyl at the highest concentration used (3 mM), caused only a slight decrease of the enzyme activity. Moreover, inducible NOS was strongly inhibited by FA72 only. All these results suggest that PF9601N could be a promising therapeutic agent in neurodegenerative disorders such as Parkinson's disease.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.